West Pharma (WST) Tops Q2 EPS by 29c ; Offers Guidance

West Pharma (NYSE: WST) reported Q2 EPS of $2.37, $0.29 better than the analyst estimate of $2.08. Revenue for the quarter came in at $872.3 million versus the consensus estimate of $839.75 million.

GUIDANCE:

West Pharma sees FY2026 EPS of $8.85-$9.05, versus the consensus of $8.62. West Pharma sees FY2026 revenue of $3.34-3.38 billion, versus the consensus of $3.33 billion.

West Pharma sees Q3 2026 EPS of $2.14-$2.24, versus the consensus of $2.12. West Pharma sees Q3 2026 revenue of $820-835 million, versus the consensus of $814.7 million.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Noodles & Company (NDLS) Tops Q2 EPS by 26c ; Offers Guidance
• Flagstar Financial, Inc. (FLG) Misses Q2 EPS by 2c
• Leerink Upgrades Edwards Lifesciences (EW) to Outperform